<DOC>
	<DOCNO>NCT01247337</DOCNO>
	<brief_summary>A phase II trial evaluate intra-hepatic chemotherapy oxaliplatin every second week combination systemic gemcitabine capecitabine combination cetuximab patient non-resectable liver metastasis cholangiocarcinoma .</brief_summary>
	<brief_title>Intra-hepatic Chemotherapy Patient With Non-resectable Liver Metastases From Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>• Informed consent Age &gt; 18 year Performance status 01 ; expect survival ≥ 3 month Patient histologically cytologically adenocarcinoma develop cell gall bladder , extra intrahepatic bile duct malignant cell consistent mention radiologic finding consistent cholangiocarcinoma Liver metastases suitable surgery local treatment Extrahepatic disease exclude PETCTscan . Prior treatment chemotherapy progression first line treatment Metastases &lt; 70 % liver neutrophile granulocyte ≥ 1.5 x 109/l og thrombocyte ≥ 100 x 109/l bilirubin &lt; 2.0 x UNL ( upper normal limit ) . creatinineclearance ≥ 30 ml/min . INR &lt; 2 . Intrahepatic treatment accomplish The patient approve multidisciplinary team • Other current prior malignant disease except adequately treat cured carcinoma situ cervix squamous cell carcinoma skin . Cytotoxic experimental treatment within 14 day period start trial medication The patient allow participate clinical trial . Any clinical symptom suggest peripheral neuropathy grade 2 Other severe medical condition Severe cardial disease AMI &lt; 1 year Presence disease prevent oral therapy Patients uncontrolled infection Pregnant lactate woman Women capable childbearing use sufficient method birth control Patients able understand treatment collaborate Prior serious unsuspected reaction treatment fluoropyrimidine Known prior hypersensitivity reaction agent Interstitial pneumonitis pulmonary fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>